Global Hematological Malignancies Market: Snapshot
Hematological malignancies, commonly known as hematological cancer, is registering a widespread prevalence across the world. According to the National Cancer Institute, hematological cancer is the fifth most commonly occurring cancer, globally, and is the second prominent reason behind the cancer death in the U.S. Researchers expect the incidence of hematological malignancies to increase further in the coming years, which will result in the growing need for its treatment, impacting the global hematological malignancies market greatly.
The opportunity in the worldwide market for hematological malignancies, which stood at US$27.4 bn in 2015, is likely to expand at a CAGR of 7.50% during the period from 2016 to 2024 and reach a value of US$51.9 bn by 2024.
The rich product pipeline and the improvement in the reimbursement scenario are likely to drive the growth of the market for hematological malignancies treatment, worldwide, in the near future. Moreover, the rising trend of patent protection is also expected to boost this market considerably in the coming years.
Demand for Immunotherapy to Remain Strong
Immunotherapy, chemotherapy, and targeted therapy are the three most common treatment methods for hematological malignancies. Among these, immunotherapy led the demand in 2015 with a share of 41.3% in the overall market. The efficiency of immunotherapy, coupled with a lower risk of side effects, has influenced its demand considerably over the last few years.
Going forward, blockbuster drugs, such as Pomalyst, Rituxan, and Revlimid, are impacting the demand for immunotherapy positively and are expected to continue doing do throughout the forecast period, leading to a substantial rise in the immunotherapy segment. Targeted therapy is also anticipated to exhibit promising growth in the near future on account of the massive investments made for the development of targeted therapy products.
Presence of Advanced Healthcare Infrastructure to Ensure Dominance of North America
The worldwide market for hematological malignancies stretches across Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. Supported by the presence of an advanced medical and healthcare infrastructure, North America market for hematological malignancies has been leading the overall market. The growing prevalence of hematological cancer, the rising awareness level of people, and the availability of modern diagnostic technologies are expected to reflect positively on the demand for hematological malignancies therapeutics in the coming years, ensuring the dominance of this regional market.
Apart from this, Asia Pacific is also projected to experience steady growth in the demand for hematological malignancies therapeutics over the next few years. The increasing incidence of blood cancer-related mutation diagnostic cases, rising count of government-supported healthcare programs, and the imminent launch of novel drugs is expected to boost the Asia Pacific market for hematological malignancies during the forecast period. Latin America and the Middle East and Africa are anticipated to offer lucrative growth prospects to market players in the years to come due to the availability of untapped opportunities in abundance.
AbbVie Inc., Bristol-Myers Squibb Co., Celgene Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. are some of the leading players in the global market for hematological malignancies.
Expanding Investments and Rising Cancer Cases to Bring Immense Growth Prospects for the Hematological Malignancies Market
The growing prevalence of cancer across the world has led to a large number of fatalities. The expanding prevalence of cancer-related cases is leading to the innovation and development of new drugs and treatment types. Diverse types of drugs and treatment options are available for various cancer types. Hematological cancer or hematological malignancy is one of the most prominent cancer types that need to be tackled effectively. Thus, all these factors will increase the growth rate of the hematological malignancies market between 2016 and 2024.
1. Preface
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Objectives
1.4. Key Questions Answered
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Acronyms Used
2.3. Research Methodology
3. Executive Summary
3.1. Global Hematological malignancies Market Snapshot
3.2. Market Opportunity Map
4. Market Overview
4.1. Product Overview
4.2. Key Industry Events
4.3. Death Rate of Leukemia, by Country
4.4. Death Rate of Cancer, by Country
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Opportunity Analysis
5.6. Porter’s Analysis
5.7. Pipeline Analysis (Phase III) till 2024
6. Global Hematological Malignancies Market Analysis, by Disease Condition
6.1. Key Findings
6.2. Introduction
6.3. Leukemia
6.4. Lymphoma
6.5. Myeloma
6.6. Key Trends
6.7. Market Attractiveness Analysis
7. Global Hematological Malignancies Market Analysis, by Therapy
7.1. Key Findings
7.2. Introduction
7.3. Chemotherapy
7.4. Immunotherapy
7.5. Targeted Therapy
7.6. Key Trends
7.7. Market Attractiveness Analysis
8. Global Hematological Malignancies Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Hospital Pharmacies
8.4. Medical Stores
8.5. E-commerce Platform
8.6. Key Trend Analysis
8.7. Market Attractiveness Analysis
9. Global Hematological Malignancies Market Analysis, by Region
9.1. North America
9.2. Europe
9.3. Asia Pacific
9.4. Latin America
9.5. Middle East & Africa
9.6. Market Attractiveness Analysis
10. North America Hematological malignancies Market Analysis
10.1. North America Hematological Malignancies Market Size Forecast, By Country, 2016-2024
10.2. North America Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
10.3. North America Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
10.4. North America Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
10.5. North America Hematological Malignancies Market Attractiveness Analysis, 2016-2024
11. Europe Hematological Malignancies Market Analysis
11.1. Europe Hematological Malignancies Market Size Forecast, By Country, 2016-2024
11.2. Europe Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
11.3. Europe Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
11.4. Europe Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
11.5. Europe Hematological Malignancies Market Attractiveness Analysis, 2016-2024
12. Asia Pacific Hematological Malignancies Market Analysis
12.1. Asia Pacific Hematological Malignancies Market Size Forecast, By Country, 2016-2024
12.2. Asia Pacific Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
12.3. Asia Pacific Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
12.4. Asia Pacific Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
12.5. Asia Pacific Hematological Malignancies Market Attractiveness Analysis, 2016-2024
13. Latin America Hematological Malignancies Market Analysis
13.1. Latin America Hematological Malignancies Market Size Forecast, By Country, 2016-2024
13.2. Latin America Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
13.3. Latin America Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
13.4. Latin America Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
13.5. Latin America Hematological Malignancies Market Attractiveness Analysis, 2016-2024
14. Middle East & Africa Hematological Malignancies Market Analysis
14.1. Middle East & Africa Hematological Malignancies Market Size Forecast, By Country, 2016-2024
14.2. Middle East & Africa Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
14.3. Middle East & Africa Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
14.4. Middle East & Africa Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
14.5. Middle East & Africa Hematological Malignancies Market Attractiveness Analysis, 2016-2024
15. Competitive Landscape
15.1. Hematological Malignancies Market Share Analysis By Company (2015)
15.2. Competition Matrix
15.2.1. Teva Pharmaceutical Industries Ltd.
15.2.2. GlaxoSmithKline plc
15.2.3. Johnson & Johnson
15.2.4. Bristol Myers Squibb
15.2.5. F. Hoffmann-La Roche Ltd.
15.2.6. Merck & Co., Inc.
15.2.7. Novartis AG
15.2.8. Pfizer, Inc.
16. Company Profiles
16.1. AbbVie, Inc.
16.1.1. Company Details
16.1.2. Company Description
16.1.3. Business Overview
16.1.4. SWOT Analysis
16.1.5. Financial Analysis
16.1.6. Strategic Overview
16.2. Bristol-Myers Squibb Company
16.2.1. Company Details
16.2.2. Company Description
16.2.3. Business Overview
16.2.4. SWOT Analysis
16.2.5. Financial Analysis
16.2.6. Strategic Overview
16.3. Celgene Corporation
16.3.1. Company Details
16.3.2. Company Description
16.3.3. Business Overview
16.3.4. SWOT Analysis
16.3.5. Financial Analysis
16.3.6. Strategic Overview
16.4. F. Hoffmann-La Roche Ltd.
16.4.1. Company Details
16.4.2. Company Description
16.4.3. Business Overview
16.4.4. SWOT Analysis
16.4.5. Financial Analysis
16.4.6. Strategic Overview
16.5. GlaxoSmithKline plc
16.5.1. Company Details
16.5.2. Company Description
16.5.3. Business Overview
16.5.4. SWOT Analysis
16.5.5. Financial Analysis
16.5.6. Strategic Overview
16.6. Johnson & Johnson
16.6.1. Company Details
16.6.2. Company Description
16.6.3. Business Overview
16.6.4. SWOT Analysis
16.6.5. Financial Analysis
16.6.6. Strategic Overview
16.7. Novartis AG
16.7.1. Company Details
16.7.2. Company Description
16.7.3. Business Overview
16.7.4. SWOT Analysis
16.7.5. Financial Analysis
16.7.6. Strategic Overview
16.8. Pfizer, Inc.
16.8.1. Company Details
16.8.2. Company Description
16.8.3. Business Overview
16.8.4. SWOT Analysis
16.8.5. Financial Analysis
16.8.6. Strategic Overview
16.9. Teva Pharmaceutical Industries Ltd.
16.9.1. Company Details
16.9.2. Company Description
16.9.3. Business Overview
16.9.4. SWOT Analysis
16.9.5. Financial Analysis
16.9.6. Strategic Overview
List of Tables
TABLE 1 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Pipeline Molecule, till 2024
TABLE 2 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 3 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Therapy, 2016–2024
TABLE 4 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 5 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Region, 2016–2024
TABLE 6 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 7 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 8 North America Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 9 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 10 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 11 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 12 Europe Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 13 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 14 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 15 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 16 Asia Pacific Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 17 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 18 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 19 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 20 Latin America Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 21 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 22 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 23 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 24 MEA Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
List of Figures
FIG. 1 Global Hematological Malignancies Market Value Share Analysis, by Disease Condition, 2015 and 2024
FIG. 2 Global Leukemia Market Revenue (US$ Mn), 2014–2024
FIG. 3 Global Lymphoma Market Revenue (US$ Mn), 2014–2024
FIG. 4 Global Myeloma Market, Revenue (US$ Mn), 2014–2024
FIG. 5 Hematological Malignancies Market Attractiveness Analysis, by Disease Condition, 2015
FIG. 6 Global Hematological Malignancies Market Value Share Analysis, by Therapy, 2015 and 2024
FIG. 7 Global Chemotherapy Market Revenue (US$ Mn), 2014–2024
FIG. 8 Global Immunotherapy Market Revenue (US$ Mn), 2014–2024
FIG. 9 Global Targeted Therapy Market, Revenue (US$ Mn), 2014–2024
FIG. 10 Hematological Malignancies Market Attractiveness Analysis, by Therapy, 2015
FIG. 11 Global Hematological Malignancies Market Value Share Analysis, by Distribution Channel, 2015 and 2024
FIG. 12 Global Hospital Pharmacies Market Revenue (US$ Mn), 2014–2024
FIG. 13 Global Medical Stores Market Revenue (US$ Mn), 2014–2024
FIG. 14 Global E-commerce Market, Revenue (US$ Mn), 2014–2024
FIG. 15 Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel, 2015
FIG. 16 North America Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 17 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 18 APAC Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 19 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 20 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 21 Global Hematological Malignancies Market Attractiveness Analysis, by Region
FIG. 22 U.S. Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 23 Canada Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 24 North America Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 25 North America Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 26 North America Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 27 North America Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 28 Germany Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 29 France Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 30 The U.K. Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 31 Italy Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 32 Spain Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 33 Rest of Europe Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 34 Europe Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 35 Europe Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 36 Europe Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 37 Europe Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 38 Japan Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 39 China Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 40 India Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 41 Rest of APAC Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 42 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 43 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Disease Condit
FIG. 44 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 45 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 46 Brazil Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 47 Mexico Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 48 Rest of LATAM Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 49 Latin America Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 50 Latin America Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 51 Latin America Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 52 Latin America Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 53 South Africa Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 54 Saudi Arabia Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 55 Rest of MEA Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 56 MEA Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 57 MEA Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 58 MEA Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 59 MEA Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 60 Hematological Malignancies Market Share Analysis, by Company (2015)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hematological Malignancies Market
